Extension of Study ZPV-200

Uterine Fibroids Clinical Trial

Official title:

A Phase 2, Multi-Center, Five-Arm, Parallel Design, Randomized, Single-Blind Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Proellex® (Telapristone Acetate) Administered Vaginally in the Treatment of Premenopausal Women With Uterine Fibroids Confirmed by Ultrasound

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01631903
• Other study ID #: ZPV-200 EXT
• Status: Completed
• Phase: Phase 2
• First received: June 27, 2012
• Last updated: April 15, 2014
• Start date: September 2012
• Est. completion date: April 2014

Study information

• Verified date: November 2012
• Source: Repros Therapeutics Inc.
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine the safety, pharmacokinetics and efficacy of four doses of vaginally administered Proellex in premenopausal women with uterine fibroids confirmed by ultrasound.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 48
• Est. completion date: April 2014
• Est. primary completion date: April 2014
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years to 47 Years

Eligibility

Inclusion Criteria:

• Healthy adult females between 18 and 47 years of age with uterine fibroids confirmed by ultrasound. Normal, or abnormal but non-clinically significant, transvaginal ultrasound. History of menstrual events occurring in regular cycles.

• Agreement not to attempt to become pregnant.

• Agreement to limit alcohol consumption to no more than 2 drinks per week and to avoid alcohol consumption within 48 hours before each visit.

• Ability to complete a daily subject diary and study procedures in compliance with the protocol.

• Agrees to use the condoms provided and no other method of birth control (hormonal methods, contraceptive sponge, spermicide or cervical cap) over the course of the study.

• Has a negative pregnancy test at the Screening and Baseline visits. An exception for the pregnancy test requirement will be granted for subjects providing verification of surgical sterilization.

• A Body Mass Index (BMI) between 18 and 39 inclusive.

• Is available for all treatment and follow-up visits.

• Subject is able to insert vaginal suppositories.

• Subject is willing to exclusively use sanitary napkins (no tampons) during study duration.

Exclusion Criteria:

• Subject is a post-menopausal woman, defined as either; six (6) months or more (immediately prior to screening visit) without a menstrual period, or prior hysterectomy and/or oophorectomy.

• Subject is pregnant or lactating or is attempting or expecting to become pregnant during the 7 month study period.

• Women with abnormally high liver enzymes or liver disease. (ALT or AST exceeding 1.5x ULN AND total bilirubin exceeding 1.5xULN at screening and confirmed on repeat).

• Received an investigational drug in the 30 days prior to the screening for this study.

• Women with a history of PCOS.

• Concurrent use of any testosterone, progestin, androgen, estrogen, anabolic steroids, DHEA or hormonal products for at least 2 weeks prior to screening and during the study.

• Use of oral contraceptives in the preceding 30 days. Use of Depo-Provera® in the preceding 6 months.

• Has an IUD in place.

• Women currently using narcotics.

• Women currently taking cimetidine or spironolactone.

• Clinically significant abnormal findings on screening examination or any condition, which in the opinion of the investigator, would interfere with the participant's ability to comply with the study instructions or endanger the participant if she took part in the study.

• Participation in study ZP-204.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Leiomyoma
• Uterine Fibroids

Intervention

Drug:
• telepristone acetate 12 mg
12 mg, vaginal capsule, once daily for 4 months
• telepristone acetate 3 mg
3 mg, vaginal capsule, once daily for 3 months
• telepristone acetate 6 mg
6 mg, vaginal capsule, once daily for 3 months
• telepristone acetate 12 mg
12 mg, vaginal capsule, once daily, for 3 months
• telepristone acetate 24 mg
24 mg, vaginal capsule, once daily for 4 months

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Repros Therapeutics Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Bleeding Scores	The primary efficacy endpoint will be bleeding assessed using the change in PBAC scores from the 4 weeks prior to Visit 2 to the 4 weeks prior to Visit 10	3 or 4 months depending on treatment arm	No

External Links

•   Sponsor's corporate web page